You're asking about **1-(2-methoxyethyl)-2-[(4-methoxyphenoxy)methyl]benzimidazole**, a complex organic molecule with a rather long and descriptive name. Let's break down its significance:
**Understanding the Structure:**
* **Benzimidazole:** The core of this molecule is benzimidazole, a heterocyclic ring system containing both benzene and imidazole rings. Benzimidazole derivatives are known for their diverse biological activities.
* **Substitutions:** The molecule has two key modifications:
* **1-(2-methoxyethyl):** A methoxyethyl group is attached to the nitrogen at the 1 position of the benzimidazole ring.
* **2-[(4-methoxyphenoxy)methyl]:** This indicates a more complex side chain. A 4-methoxyphenoxy group (a benzene ring with a methoxy group) is connected via a methylene (-CH2-) group to the nitrogen at the 2 position of the benzimidazole ring.
**Importance in Research:**
This specific benzimidazole derivative is likely important for research because of its potential applications in:
* **Pharmacology:** Benzimidazole derivatives are often explored for their pharmacological properties. This molecule might exhibit activity as:
* **Anti-cancer agents:** Benzimidazoles can interfere with cell division and growth, potentially acting as anti-cancer drugs.
* **Anti-inflammatory agents:** Some benzimidazoles have been shown to suppress inflammation.
* **Antimicrobial agents:** These compounds can inhibit the growth of bacteria and other microorganisms.
* **Materials Science:** The structure of the molecule suggests it could be used in:
* **Polymer synthesis:** Benzimidazoles are known to be building blocks for polymers with unique properties.
* **Organic electronics:** The presence of aromatic rings could make this molecule relevant in organic semiconductors or photovoltaics.
**To pinpoint its exact importance, we need more information:**
* **What research is being conducted?** Is it related to drug development, materials science, or something else?
* **What are the specific properties of the molecule?** What are its solubility, melting point, or biological activity?
**Further Research:**
To learn more about this specific benzimidazole derivative, you can:
* **Search scientific databases:** Use databases like PubMed or SciFinder to find relevant research articles.
* **Check chemical suppliers:** Companies like Sigma-Aldrich or Thermo Fisher Scientific may provide detailed information on the compound.
* **Contact researchers:** If you're aware of research groups working in related areas, reach out to them directly.
By gathering more context, you can better understand the significance of this particular benzimidazole derivative in research.
ID Source | ID |
---|---|
PubMed CID | 2946898 |
CHEMBL ID | 1389606 |
CHEBI ID | 131292 |
Synonym |
---|
STL290773 |
AF-399/41980591 |
1-(2-methoxyethyl)-2-[(4-methoxyphenoxy)methyl]-1h-benzimidazole |
MLS000099688 , |
smr000074573 |
AKOS001689565 |
CHEBI:131292 |
1-(2-methoxyethyl)-2-[(4-methoxyphenoxy)methyl]benzimidazole |
HMS2310D20 |
CCG-24945 |
F1670-0098 |
1-(2-methoxyethyl)-2-((4-methoxyphenoxy)methyl)-1h-benzo[d]imidazole |
612527-23-8 |
1-(2-methoxyethyl)-2-[(4-methoxyphenoxy)methyl]-1h-1,3-benzodiazole |
CHEMBL1389606 |
HMS3430O19 |
Z57841877 |
Q27225057 |
Class | Description |
---|---|
benzimidazoles | An organic heterocyclic compound containing a benzene ring fused to an imidazole ring. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
ATAD5 protein, partial | Homo sapiens (human) | Potency | 25.9290 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 25.1189 | 0.0013 | 18.0743 | 39.8107 | AID926; AID938 |
nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 3.9811 | 0.2818 | 9.7212 | 35.4813 | AID2326 |
ras-related protein Rab-9A | Homo sapiens (human) | Potency | 3.9811 | 0.0002 | 2.6215 | 31.4954 | AID485297 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |